Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecloderm versus Lotricomb versus vehicle in inflamed cutaneous candidiasis
2021-003790-65Phase 3Active
- Sponsor
- Dermapharm
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meclocycline, clotrimazole + betamethasone, clotrimazole and betamethasone dipropionate in cutaneous candidiasis (3 arms), sponsored by Dermapharm. Primary endpoint: Treatment success at end of treatment. Started Dec 2021; status: active.
02
Drugs
meclocyclineclotrimazole + betamethasoneclotrimazolebetamethasone dipropionate
03
Conditions
cutaneous candidiasis
Beyond the preview
Go deeper on 2021-003790-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003790-65.